U.S. Markets closed

What’s Pulling Down Allergan’s Share Price in 2019?

Margaret Patrick
What’s Pulling Down Allergan’s Share Price in 2019?

On March 6, Allergan (AGN) issued a press release announcing the failure of its investigational therapy rapastinel to meet the primary and secondary end points in three pivotal trials evaluating it as an adjunctive therapy in combination with antidepressant therapy in major depressive disorder indications.